Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2%

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,410,000 shares, an increase of 5.2% from the January 15th total of 1,340,000 shares. Currently, 4.6% of the company's stock are sold short. Based on an average daily volume of 419,500 shares, the days-to-cover ratio is currently 3.4 days.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. nVerses Capital LLC lifted its holdings in iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company's stock worth $26,000 after buying an additional 1,700 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of iTeos Therapeutics in the 3rd quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of iTeos Therapeutics in the 4th quarter worth approximately $42,000. Virtus ETF Advisers LLC lifted its holdings in shares of iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after purchasing an additional 3,293 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company's stock worth $72,000 after purchasing an additional 2,646 shares during the last quarter. Institutional investors own 97.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ITOS shares. HC Wainwright restated a "buy" rating and set a $21.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, January 16th. Wells Fargo & Company lowered their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an "overweight" rating for the company in a research note on Thursday, December 19th. Finally, Wedbush restated an "outperform" rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research note on Friday, January 10th.

iTeos Therapeutics Stock Down 0.3 %

NASDAQ:ITOS traded down $0.02 during trading hours on Thursday, reaching $7.48. 155,602 shares of the stock were exchanged, compared to its average volume of 255,133. The firm has a 50 day simple moving average of $7.61 and a 200-day simple moving average of $10.11. iTeos Therapeutics has a 52 week low of $7.06 and a 52 week high of $18.75. The stock has a market capitalization of $273.27 million, a P/E ratio of -2.37 and a beta of 1.38.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.